Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Urology, Erasmus Medical Centre, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Acta Oncol. 2022 Aug;61(8):1019-1025. doi: 10.1080/0284186X.2022.2101381. Epub 2022 Jul 26.
Organ-sparing treatment for muscle-invasive bladder cancer by maximal transurethral removal of the tumor (TURB) followed by chemoradiation (CRT) has shown promising results in recent studies, and is therefore considered to be an acceptable alternative for the standard of radical cystectomy (RC) in selected patients. We report on outcomes in a single-center, retrospective CRT cohort in comparison to a RC and radiotherapy only (RT) cohort.
The patient population included = 84 CRT patients, = 93 RC patients, and = 95 RT patients. Primary endpoints were local control (LC) up to 2 years and overall survival (OS) up to 5 years. Cox regression was performed to determine risk factors for LC and OS in the CRT group. Acute genito-urinary (GU) and gastro-intestinal (GI) toxicity were scored with CTCAE version 4 for the RT and CRT cohort. Logistic regression was used to determine risk factors for toxicity. We followed the EQUATOR guidelines for reporting, using the STROBE checklist for observational research.
Baseline characteristics were different between the treatment groups with in particular worse comorbidity scores and higher age in the RT cohort. The CRT schedule was completed by 96% of the patients. LC at 2 years was 83.4% (90% CI 76.0-90.8) for CRT 70.9% (62.2-79.6) for RC and 67.0% (56.8-77.2) for RT. OS at 5 years was 48.9% (38.4-59.4) for CRT 46.6% (36.4-56.8) for RC, and 27.6% (19.4-35.8) for RT. High T stage was significantly associated with worse LC and OS in the CRT group. GU/GI toxicity grade ≥2 occurred in 43 (48.3%) RT patients and 38 (45.2%) CRT patients.
The organ-preserving strategy with CRT was feasible and tolerable in this patient population, and the achieved LC and OS were satisfactory in comparison to the RC cohort and literature.
通过最大限度地经尿道切除肿瘤(TURB)联合化疗放疗(CRT)对肌层浸润性膀胱癌进行保器官治疗,在最近的研究中显示出良好的效果,因此被认为是在某些患者中替代根治性膀胱切除术(RC)的一种可接受的选择。我们报告了单中心回顾性 CRT 队列与 RC 和单纯放疗(RT)队列的结果。
患者人群包括 84 例 CRT 患者、93 例 RC 患者和 95 例 RT 患者。主要终点是 2 年内局部控制(LC)和 5 年内总生存(OS)。采用 COX 回归分析 CRT 组 LC 和 OS 的危险因素。采用 CTCAE 第 4 版对 RT 和 CRT 组的急性泌尿生殖系统(GU)和胃肠道(GI)毒性进行评分。采用 logistic 回归分析确定毒性的危险因素。我们遵循报告的 EQUATOR 指南,使用 STROBE 清单进行观察性研究。
治疗组之间的基线特征不同,特别是 RT 组的合并症评分较差,年龄较大。96%的患者完成了 CRT 治疗计划。2 年时 LC 为 CRT 组 83.4%(90%CI 76.0-90.8)、RC 组 70.9%(62.2-79.6)和 RT 组 67.0%(56.8-77.2)。5 年时 OS 为 CRT 组 48.9%(38.4-59.4)、RC 组 46.6%(36.4-56.8)和 RT 组 27.6%(19.4-35.8)。T 期较高与 CRT 组较差的 LC 和 OS 显著相关。43 例(48.3%)RT 患者和 38 例(45.2%)CRT 患者发生≥2 级 GU/GI 毒性。
在该患者人群中,CRT 的保器官策略是可行且可耐受的,与 RC 队列和文献相比,获得的 LC 和 OS 令人满意。